Biotech

Moleculin Biotech announced it will meet with the European Medicines Agency (EMA) for the clinical trial authorization study of Annamycin treating acute myeloid leukemia.

Moleculin Biotech (NASDAQ:MBRX) announced it will meet with the European Medicines Agency (EMA) for the clinical trial authorization study of Annamycin treating acute myeloid leukemia.
As quoted in the press release:

The European Medicines Agency is the European equivalent to the US Food and Drug Administration (FDA) and oversees the approval of new drugs for the European Union.
“With our planned clinical trial for Annamycin in the US and Poland which may begin shortly, dependent upon the filing and allowance of an IND with the FDA,” commented Walter Klemp, Chairman and CEO of Moleculin, “we want to be in a position to move quickly with Annamycin in the rest of Europe. This meeting will lay the groundwork for expanding Annamycin’s market throughout the European Union.”

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX19994.78+72.97
TSXV593.53-8.22
DOW33592.92+56.22
S&P 5003991.73+34.48
NASD11358.41+162.19
ASX7141.60-4.70

COMMODITIES

Commodities
Gold1779.17-1.49
Silver21.83+0.24
Copper3.79-0.03
Palladium2089.25-6.76
Platinum1015.50-0.50
Oil86.07-0.85
Heating Oil3.51+0.09
Natural Gas5.88-0.15

DOWNLOAD FREE REPORTS

×